<DOC>
	<DOCNO>NCT00120185</DOCNO>
	<brief_summary>Interleukin-2 ( IL-2 ) increase number CD4 cell HIV-1 infect patient highly active antiretroviral therapy ( HAART ) CD4 cell count 200/mm3 , activity patient without antiretroviral therapy unknown . This study test efficacy safety IL-2 naïve patient CD4 count 300 500/m3 .</brief_summary>
	<brief_title>Efficacy Using Interleukin-2 Antiretroviral Naïve HIV Patients ( ANRS119 )</brief_title>
	<detailed_description>IL-2 produce naturally body help CD4 cell multiply . In early study HIV-infection , patient control viral load antiretroviral therapy high level CD4 cell count ( 200/mm3 ) receive IL-2 , experience increase CD4 cell count superior observed antiretroviral therapy alone . The efficacy IL-2 viral load high patient receive antiretroviral therapy know . The purpose multicentric national study compare effect IL-2 versus treatment HIV naïve patient . One hundred thirty HIV-1-infected patient , CD4 count 300 500/mm3 , randomly assign one two treatment group : IL-2 treatment . The group IL-2 receive dose 4.5 million international unit subcutaneous injection twice day 5 day ( total 5 cycle , end Week 96 ) , first three cycle 8 week apart . Evaluation do week 96 . The primary endpoint proportion patient reach absolute CD4 count 300/mm3 Week 96 . Secondary endpoint include occurrence HIV-related event , drug safety evolution CD4 cell HIV RNA HIV DNA load time .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Adult patient proven HIV1infection No prior exposition antiretrovirals CD4 cell count 300 500/mm3 Signed write inform consent Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Interleukin-2</keyword>
</DOC>